Single Bolus Recombinant Nonimmunogenic Staphylokinase (Fortelyzin) and Bolus Infusion Alteplase in Patients With AIS
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 336 participants.
Also called NCT03151993
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 336 participants
- Sponsor
- Registry
-
NCT03151993
-
- Other papers using this trial's data
- Non-immunogenic recombinant staphylokinase versus alteplase for patients with acute ischaemic stroke 4·5 h after symptom onset in Russia (FRIDA): a randomised, open label, multicentre, parallel-group, non-inferiority trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Russia
- Registry status
- Completed
Technical summary
Registry record NCT03151993. Randomized; no masking; primary purpose treatment. Start 2017-03-18 (actual); primary completion 2019-03-23 (actual). Results posted on 2025-04-02.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Single Bolus Recombinant Nonimmunogenic Staphylokinase (Fortelyzin) and Bolus Infusion Alteplase in Patients With AIS
- Condition
- Ischemic Stroke
- Intervention (Drug)
- Recombinant staphylokinase
- Intervention (Drug)
- Alteplase
- Lead sponsor
- Supergene, LLC
Record details
- Record id
cardio:ct-nct03151993- Content hash
04f24494faf490097d3d4bb9099d8a87e08d5bf79b66d029c99739226c24e488